奥赛康(002755) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥508,555,172.17, representing a 13.39% increase compared to ¥448,492,136.86 in the same period last year[5]. - Net profit attributable to shareholders increased by 73.50% to ¥54,730,335.25 from ¥31,544,742.35 year-on-year[5]. - The net profit after deducting non-recurring gains and losses rose by 86.93% to ¥43,997,226.18 compared to ¥23,536,136.49 in the previous year[5]. - The company reported a net profit margin improvement, with net profit increasing due to higher operating revenue and controlled costs[17]. - The net profit for the current period is 51,027,030.36, compared to 26,431,563.79 in the previous period, representing a growth of approximately 93.3%[18]. - The company's total profit for the current period is 51,772,395.44, compared to 28,800,104.97 in the previous period, showing an increase of about 80%[18]. - Basic and diluted earnings per share for the current period are both 0.06, compared to 0.03 in the previous period, reflecting a 100% increase[18]. Assets and Liabilities - The company's total assets increased by 4.97% to ¥4,248,993,672.56 from ¥4,047,628,524.03 at the end of the previous year[5]. - Current assets totaled ¥2,776,467,117.38, up from ¥2,568,164,247.66, indicating an increase of 8.1%[14]. - Non-current assets slightly decreased to ¥1,472,526,555.18 from ¥1,479,464,276.37, a decline of 0.5%[15]. - Total liabilities rose to ¥1,023,615,507.15 from ¥905,387,149.91, marking an increase of 13.0%[15]. - The company's equity attributable to shareholders increased to ¥3,145,015,100.10 from ¥3,062,651,954.20, a growth of 2.7%[16]. Cash Flow - The cash flow from operating activities decreased by 4.99% to ¥188,485,376.51 from ¥198,390,225.98 year-on-year[5]. - Operating cash flow net amount is 188,485,376.51, slightly down from 198,390,225.98 in the previous period, reflecting a decrease of approximately 4.6%[19]. - Cash flow from investment activities shows a net outflow of -412,744,811.32, compared to -50,456,332.08 in the previous period, indicating a significant increase in cash outflow[19]. - The company received cash from sales of goods and services totaling 578,669,629.09, an increase from 484,724,987.26 in the previous period, representing a growth of approximately 19.5%[19]. - The company’s cash inflow from financing activities is 47,000,000.00, significantly higher than 10,000,000.00 in the previous period, marking a 370% increase[20]. Operating Performance - Total operating revenue for the current period reached ¥508,555,172.17, an increase of 13.4% compared to ¥448,492,136.86 in the previous period[17]. - Total operating costs amounted to ¥467,198,066.18, up from ¥429,181,894.86, reflecting a growth of 8.8%[17]. - Research and development expenses were ¥59,006,421.58, a decrease of 7.9% from ¥63,512,044.42 in the previous period[17]. Intangible Assets and Government Support - The company reported a significant increase in intangible assets by 249.65% to ¥511,688,370.51, attributed to the successful launch of innovative drugs[9]. - The company received government subsidies amounting to ¥5,362,520.04, which are closely related to its normal business operations[6]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,819[11]. - Cash and cash equivalents decreased to ¥1,126,351,078.05 from ¥1,411,460,031.75, a decline of 20.1%[14]. - Cash and cash equivalents at the end of the period amount to 1,110,415,439.12, down from 1,153,337,238.95 in the previous period, a decrease of about 3.7%[20]. Comprehensive Income - The total comprehensive income for the current period is 52,672,280.11, up from 24,531,226.53 in the previous period, indicating an increase of about 114.5%[18]. - The company reported other comprehensive income after tax of 1,645,249.75, compared to -1,900,337.26 in the previous period, indicating a turnaround in this area[18].